Related Experiment Videos
Selective pulmonary vasodilators for severe pulmonary hypertension: comparison between endpoints
Joana Feliciano1, Duarte Cacela, Ana Agapito
1Serviço de Cardiologia, Hospital de Santa Marta, Lisboa, Portugal. joanafeliciano@netcabo.pt
Summary
Selective vasodilator therapy improved pulmonary arterial hypertension (PAH) endpoints, including the 6-minute walk test and echocardiographic measures. However, these endpoints did not correlate, limiting their use as interchangeable follow-up tools.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Pharmacology
Background:
- Severe pulmonary arterial hypertension (PAH) management has advanced with selective pulmonary vasodilators.
- Therapeutic options include prostacyclin analogs and endothelin receptor antagonists.
Purpose of the Study:
- To correlate the 6-minute walk test, Tei index, and peak tricuspid regurgitation velocity in PAH patients undergoing vasodilator therapy.
- To assess the utility of these endpoints in monitoring treatment response.
Main Methods:
- Eleven patients with severe PAH were followed for 11 months.
- Eight patients received iloprost or bosentan therapy.
- Pearson's correlation coefficient was used to assess endpoint correlation.
Main Results:
- No significant correlation was found between the 6-minute walk test, Tei index, and peak tricuspid regurgitation velocity before or after therapy.
- All three endpoints showed improvement following selective vasodilatory treatment.
Conclusions:
- Therapeutic response in PAH can be monitored using the 6-minute walk test or echocardiographic measures.
- The lack of correlation between these endpoints suggests they cannot be used interchangeably for patient follow-up.